Compare Recursion Pharmaceuticals Inc (RXRX) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs AT&T Inc. — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B), while AT&T Inc. trades at $25.2 (market cap $175.42B). The key difference: AT&T Inc. is far larger — about 94.3× Recursion Pharmaceuticals Inc's market cap, and AT&T Inc. pays a 4.34% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | T | |
|---|---|---|
Market Cap | $1.86B | $175.42B |
Sector | Health | Media |
52-Week High | $6.79 | $29.62 |
52-Week Low | $2.84 | $20.49 |
Enterprise Value | $1.38B | $320.74B |
Dividend Yield | — | 4.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
AT&T (T) trades at $25.61, down slightly by 0.21% on the day. The stock exhibits a bullish technical trend with strong moving average signals, while oscillators remain neutral. Fundamentally, the company reported robust earnings, beating estimates in recent quarters, with a net income margin of 16.94% and attractive valuation ratios like a P/E of 8.45. Recent news highlights strategic focus on fiber and wireless growth, including a partnership with Amazon for satellite broadband.
The outlook for AT&T is positive, supported by consistent earnings beats, a solid dividend, and strategic initiatives in fiber and 5G. Key risks include high debt levels and intense competition. Analysts maintain a consensus buy rating with a $27.69 price target, suggesting potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
